## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Understanding Momentum Shifts in (IQV)**
- Source: Stock Traders Daily | 20251221T075600 | Neutral | Relevance: 100%
- Iqvia Holdings Inc. (NYSE: IQV) is exhibiting a neutral sentiment across all horizons, suggesting a sideways action. AI models have generated three distinct trading strategies for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The stock shows a mid-channel oscillation pattern, with an exceptional 46.2:1 risk-reward short setup.

**2. Osaic Holdings Inc. Grows Position in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251220T111317 | Bullish | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 32.0% in Q2, boosting its total to 71,103 shares valued at over $11 million. This comes as IQVIA reported strong quarterly earnings, beating analyst estimates, and received several upgraded ratings and price targets from major financial institutions. Institutional investors now hold approximately 89.62% of the company's stock, reflecting strong market confidence.

**3. IQVIA (NYSE:IQV) Raised to "Buy" at Wall Street Zen**
- Source: MarketBeat | 20251220T070419 | Bullish | Relevance: 100%
- Wall Street Zen upgraded IQVIA (NYSE:IQV) from a "hold" to a "buy" rating. This follows several other firms, including UBS Group and HSBC, which also raised their price targets and ratings for IQV. The company recently reported strong quarterly earnings, surpassing analyst estimates, and has seen notable insider transactions and institutional trading activity.

**4. Thermo Fisher Scientific (TMO): Revisiting Valuation After New Alzheimerâ€™s Registry and Ongoing Capital Deployment**
- Source: Simply Wall Street | 20251220T000923 | Neutral | Relevance: 65%
- Thermo Fisher Scientific (TMO) recently enrolled a patient in its new PPD CorEvitas Alzheimer's Disease Registry, reinforcing its position in healthcare infrastructure. The stock has seen significant returns over the past 90 days and five years, suggesting rebuilding momentum. Despite trading near $567, it remains undervalued by approximately 6% intrinsically and 12% below consensus targets, prompting investors to assess if this is a good entry point.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.2B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 17.3 |
| Current P/E | 18.9 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.2% (minimal 5-day change). Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.23x) but short-term weakness (below SMA20). MACD histogram bearish (-0.78), momentum weakening. RSI neutral at 54. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.16% (CS: 55) | Neutral |
| RSI_14 | 54.1 | Neutral |
| MACD Histogram | -0.78 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.230x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.33
- **Stop Loss:** $213.89 (4.7% risk)
- **Target:** $234.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $25,573.62
- **Portfolio %:** 25.57%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*